861 related articles for article (PubMed ID: 31082511)
1. Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles.
Partikel K; Korte R; Stein NC; Mulac D; Herrmann FC; Humpf HU; Langer K
Eur J Pharm Biopharm; 2019 Aug; 141():70-80. PubMed ID: 31082511
[TBL] [Abstract][Full Text] [Related]
2. Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS.
Gossmann R; Fahrländer E; Hummel M; Mulac D; Brockmeyer J; Langer K
Eur J Pharm Biopharm; 2015 Jun; 93():80-7. PubMed ID: 25813886
[TBL] [Abstract][Full Text] [Related]
3. Identification of main influencing factors on the protein corona composition of PLGA and PLA nanoparticles.
Spreen H; Behrens M; Mulac D; Humpf HU; Langer K
Eur J Pharm Biopharm; 2021 Jun; 163():212-222. PubMed ID: 33862242
[TBL] [Abstract][Full Text] [Related]
4. Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin.
Samkange T; D'Souza S; Obikeze K; Dube A
J Pharm Pharmacol; 2019 Oct; 71(10):1497-1507. PubMed ID: 31385295
[TBL] [Abstract][Full Text] [Related]
5. Serum type and concentration both affect the protein-corona composition of PLGA nanoparticles.
Partikel K; Korte R; Mulac D; Humpf HU; Langer K
Beilstein J Nanotechnol; 2019; 10():1002-1015. PubMed ID: 31165027
[No Abstract] [Full Text] [Related]
6. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.
Avgoustakis K
Curr Drug Deliv; 2004 Oct; 1(4):321-33. PubMed ID: 16305394
[TBL] [Abstract][Full Text] [Related]
7. Comparative whole corona fingerprinting and protein adsorption thermodynamics of PLGA and PCL nanoparticles in human serum.
Ndumiso M; Buchtová N; Husselmann L; Mohamed G; Klein A; Aucamp M; Canevet D; D'Souza S; Maphasa RE; Boury F; Dube A
Colloids Surf B Biointerfaces; 2020 Apr; 188():110816. PubMed ID: 31991290
[TBL] [Abstract][Full Text] [Related]
8. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption.
Gref R; Lück M; Quellec P; Marchand M; Dellacherie E; Harnisch S; Blunk T; Müller RH
Colloids Surf B Biointerfaces; 2000 Oct; 18(3-4):301-313. PubMed ID: 10915952
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
10. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats.
Li Y; Pei Y; Zhang X; Gu Z; Zhou Z; Yuan W; Zhou J; Zhu J; Gao X
J Control Release; 2001 Apr; 71(2):203-11. PubMed ID: 11274752
[TBL] [Abstract][Full Text] [Related]
11. PEGylation strategies for active targeting of PLA/PLGA nanoparticles.
Betancourt T; Byrne JD; Sunaryo N; Crowder SW; Kadapakkam M; Patel S; Casciato S; Brannon-Peppas L
J Biomed Mater Res A; 2009 Oct; 91(1):263-76. PubMed ID: 18980197
[TBL] [Abstract][Full Text] [Related]
12. In vitro degradation of nanoparticles prepared from polymers based on DL-lactide, glycolide and poly(ethylene oxide).
Zweers ML; Engbers GH; Grijpma DW; Feijen J
J Control Release; 2004 Dec; 100(3):347-56. PubMed ID: 15567501
[TBL] [Abstract][Full Text] [Related]
13. Uptake of polymeric nanoparticles in a human induced pluripotent stem cell-based blood-brain barrier model: Impact of size, material, and protein corona.
Onyema HN; Berger M; Musyanovych A; Bantz C; Maskos M; Freese C
Biointerphases; 2021 Mar; 16(2):021004. PubMed ID: 33765771
[TBL] [Abstract][Full Text] [Related]
14. Nanotechnology for biomaterials engineering: structural characterization of amphiphilic polymeric nanoparticles by 1H NMR spectroscopy.
Hrkach JS; Peracchia MT; Domb A; Lotan N; Langer R
Biomaterials; 1997 Jan; 18(1):27-30. PubMed ID: 9003893
[TBL] [Abstract][Full Text] [Related]
15. Biodegradable self-assembled nanoparticles of PEG-PLGA amphiphilic diblock copolymer as a promising stealth system for augmented vinpocetine brain delivery.
Ahmed OAA; Badr-Eldin SM
Int J Pharm; 2020 Oct; 588():119778. PubMed ID: 32805381
[TBL] [Abstract][Full Text] [Related]
16. A robust systematic design: Optimization and preparation of polymeric nanoparticles of PLGA for docetaxel intravenous delivery.
Rafiei P; Haddadi A
Mater Sci Eng C Mater Biol Appl; 2019 Nov; 104():109950. PubMed ID: 31499976
[TBL] [Abstract][Full Text] [Related]
17. Design and Development of Bioceramic Based Functionalized PLGA Nanoparticles of Risedronate for Bone Targeting: In-vitro Characterization and Pharmacodynamic Evaluation.
Rawat P; Manglani K; Gupta S; Kalam A; Vohora D; Ahmad FJ; Talegaonkar S
Pharm Res; 2015 Oct; 32(10):3149-58. PubMed ID: 25840949
[TBL] [Abstract][Full Text] [Related]
18. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
19. Impact of PEG and PEG-b-PAGE modified PLGA on nanoparticle formation, protein loading and release.
Rietscher R; Czaplewska JA; Majdanski TC; Gottschaldt M; Schubert US; Schneider M; Lehr CM
Int J Pharm; 2016 Mar; 500(1-2):187-95. PubMed ID: 26784983
[TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil-loaded PLA/PLGA PEG-PPG-PEG polymeric nanoparticles: formulation, in vitro characterization and cell culture studies.
Ocal H; Arica-Yegin B; Vural I; Goracinova K; Caliş S
Drug Dev Ind Pharm; 2014 Apr; 40(4):560-7. PubMed ID: 23596973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
